# metabolic dysfunction-associated steatohepatitis (MASH) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: DISEASE-STATE
- Tissue / sample source: liver tissue
- Comparison or endpoint: MASH/NASH versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: f634f84e95c290ce4195eb13604b114b4c86ce8adb76238e59c436c955ac43b9
- Response HTTP status: 200
- Prompt tokens: 25508
- Completion tokens: 16437
- Reasoning tokens: 8584
- Total tokens: 41945
- API requests reported: 2
- Elapsed seconds: 147.85
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1019.869
- Question handoff seconds: 1032.938
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: MiniMax

---
<think>The user wants a comprehensive, evidence-grounded biological interpretation of a transcriptomic dataset comparing MASH/NASH versus healthy liver tissue. Let me carefully analyze the data.

**Key observations from the dataset:**

1. **100 selected genes** (49 downregulated, 51 upregulated), all with FDR ≤ 0.01
2. **Effect sizes**: log2FC ranging from -4.59 (PCDH20) to +4.91 (TREM2)
3. **Strong statistical significance**: FDRs down to ~1e-14

**Major themes I can identify from the gene list:**

### Upregulated genes (MASH > Control):
- **Kupffer cell/macrophage markers**: TREM2 (log2FC=+4.91, highest), MARCO(-2.84, actually DOWN), CFD... wait, let me re-read
  - TREM2: +4.91 (UP) - key Kupffer cell/monocyte-derived macrophage marker
  - CD163: -2.52 (DOWN) - wait, this is downregulated
  - MARCO: -2.84 (DOWN) - macrophage scavenger receptor
  - MRC1: -2.10 (DOWN) - M2 macrophage marker
  - FOLR2: -2.04 (DOWN)
  - SIGLEC1: -2.12 (DOWN)
  - CD5L: -2.90 (DOWN)
  - TIMD4: -4.28 (DOWN)
  - SPIC: -2.62 (DOWN)
  - CSF1R: -1.99 (DOWN)
  
  Actually, many of the classic Kupffer cell/resident macrophage markers are DOWNREGULATED, while TREM2 is strongly UP. This is the classic "MASH macrophage" signature where TREM2+ macrophages (lipid-associated macrophages or LAMs) expand while tissue-resident Kupffer cells contract.

- **Inflammatory/chemokine**: CXCL10 (+3.46), UBD (+4.15), TNFRSF12A (+3.27)
- **ECM/fibrosis**: HS3ST2 (+3.72), P4HA1 (-3.19, actually DOWN)
- **Cell cycle/proliferation**: FOXM1 (+2.14), TP53I3 (+3.26), EME1 (+1.88)
- **Mitochondrial/energy**: UQCRBP1 (+3.73), CYCS (+1.56)
- **Other markers**: TINAGL1 (also known as lipocalin-7, adrenal-specific), CAPG (+2.57), CAST (+4.02), FABP5 (+2.85), S100A14 (+1.78), MANF (+1.85)

### Downregulated genes:
- **Resident macrophage/Kupffer cell markers**: MARCO, CD163, MRC1, CD5L, TIMD4, SPIC, FOLR2, SIGLEC1, SIGLEC11, CSF1R, MPEG1
- **Kupffer cell identity genes**: CD163, MARCO, MRC1, VSIG4 (not in list)
- **Endothelial/sinusoidal markers**: LYVE1 (-2.73), CDH5 (-1.38), LDB2 (-1.53)
- **Adhesion**: VCAM1 (-2.38), PCDH20 (-4.59), CDH23 (-1.90), CDH5 (-1.38)
- **Complement**: CR1 (-3.61), CFP (-1.86), CD5L (-2.90)
- **Scavenger receptors**: MARCO (-2.84), SCARA (not in list), MRC1 (-2.10)
- **Transcription regulators**: TCF7L1 (-1.53), ETV5 (-1.93), FOXM1 (+2.14, UP)
- **Liver metabolic genes**: CBS (-1.25) - cystathionine beta-synthase, SCLY (-1.28) - selenocysteine lyase

### String/Network evidence:
- TREM2 - CSF1R: OmniPath ConnectomeDB (signaling)
- CD163 - MARCO: STRING (both macrophage)
- CD163 - MRC1 - SIGLEC1: STRING cluster
- C3 - CFP - CR1: STRING (complement cascade)
- CTNNB1 - CDH5, FOXM1, TCF7L1: STRING (Wnt signaling)
- HS3ST2 - NDST3: STRING (heparan sulfate biosynthesis)
- HSPA5 - CD5L, MANF: STRING (ER stress/UPR)

### Key literature:
- PMID 39497821: "Identification and validation of efferocytosis-related biomarkers for the diagnosis of MASH based on bioinformatics analysis and machine learning" - very relevant context
- PMID 42089112: "Integrative transcriptomic analysis reveals miR-26a-5p downregulation and a potential predictive gene signature for the progression of metabolic liver disease."
- PMID 29503738: CX3CR1 in tissue-resident macrophages

### Pathway/ontology batch:
- GO: Cell-Cell Adhesion Via Plasma-Membrane Adhesion Molecules (GO:0098742)
- GO: Regulation Of Complement Activation, Classical Pathway (GO:0030450)
- GO: Negative Regulation Of Amyloid Fibril Formation (GO:1905907)
- KEGG: Aminoacyl-tRNA biosynthesis, Tuberculosis, Malaria
- STRING edges: 50

**Evidence adjudication notes:**
- No independent cohort validation available
- All pathway/network/literature records are contextual
- Direction counts: 49 down, 51 up, so balanced

**Core biological programs to identify:**

1. **TREM2+ Lipid-Associated Macrophage (LAM) expansion vs. loss of tissue-resident Kupffer cells**
   - UP: TREM2 (+4.91, strongest signal), CXCL10 (+3.46), UBD (+4.15), FABP5 (+2.85), CAPG (+2.57), MANF (+1.85)
   - DOWN: MARCO, CD163, MRC1, CD5L, TIMD4, SPIC, FOLR2, SIGLEC1, SIGLEC11, CSF1R, MPEG1, LYVE1
   - This is a well-established MASH signature (recently described in multiple scRNA-seq studies)

2. **Inflammatory signaling and chemotaxis**
   - UP: CXCL10, UBD, TNFRSF12A, DUSP8
   - Reactions: interferon response, NF-κB, chemokine signaling

3. **Complement dysregulation**
   - DOWN: CR1, CFP, CD5L, VSIG4 (not in list)
   - GO: Regulation Of Complement Activation, Classical Pathway (GO:0030450)

4. **Endothelial/sinusoidal remodeling and loss of liver zonation**
   - DOWN: LYVE1, CDH5, LDB2, VCAM1, PCDH20, CDH23
   - GO: Cell-Cell Adhesion Via Plasma-Membrane Adhesion Molecules

5. **Fibrogenic/ECM remodeling**
   - UP: HS3ST2 (+3.72), TNFRSF12A
   - DOWN: P4HA1 (-3.19), TINAGL1, FBN (not in list)

6. **DNA damage/replication stress**
   - UP: FOXM1, TP53I3, EME1, MTHFD1L, MTRNR2L8
   - Cell cycle dysregulation in hepatocytes under lipotoxic stress

Let me structure the response around the most coherent programs. I should pick the top 5.

**Key genes/modules to highlight:**
1. TREM2 - the central LAM marker
2. CXCL10 - inflammatory chemokine
3. MARCO/CD163/MRC1 - Kupffer cell identity loss
4. CR1/CFP/CD5L - complement suppression
5. LYVE1/CDH5 - sinusoidal endothelial
6. HS3ST2/NDST3 - heparan sulfate
7. FOXM1 - proliferation/DNA damage
8. CXCL10/UBD - inflammatory

Let me write the response now. I'll be careful to:
- Use uploaded statistics as primary
- Distinguish evidence types
- Note no independent cohort replication
- Be appropriately cautious about causation
- Focus on biological plausibility
- Keep programs truly distinct and grounded in multiple genes

Let me also note that I should distinguish between:
- Direct evidence: the uploaded log2FC/p/FDR
- Pathway/ontology: from RAG batch
- Network: STRING/OmniPath
- Disease association: from external databases
- Literature: from PubMed/Europe PMC

Let me draft the response now.

Looking at the data more carefully:

**Strongly upregulated (log2FC > 3):**
- TREM2 (4.91), UBD (4.15), TRNC (4.07), TRNL2 (3.86), LOC105371873 (3.82), LOC105377700 (3.93), CAST (4.02), UQCRBP1 (3.73), DTNA (3.72), HS3ST2 (3.72), TMEM154 (3.71), TRNY (3.57), CXCL10 (3.46), LOC107984754 (3.64), DUSP8 (3.49), MIR12136 (3.18), TP53I3 (3.26), TNFRSF12A (3.27), MIR6717 (actually down: -2.24)

**Strongly downregulated (log2FC < -3):**
- PCDH20 (-4.59), TIMD4 (-4.28), DIO3OS (-3.88), CR1 (-3.61), LOC107986183 (-3.64), MS4A6E (-3.52), P4HA1 (-3.19), CD81-AS1 (-2.96), CD5L (-2.90), MARCO (-2.84), LYVE1 (-2.73), MAST1 (-2.73), SPIC (-2.62)

This is a strong signal. The signature is clearly dominated by:
- Macrophage biology (TREM2 up + many Kupffer markers down)
- Inflammation (CXCL10, UBD, TNFRSF12A up)
- Complement down (CR1, CFP, CD5L)
- Sinusoidal endothelial remodeling (LYVE1, CDH5 down)
- Some fibrosis hint (HS3ST2 up, P4HA1 down)

Note: Many mitochondrial tRNA genes (TRNK, TRNL2, TRNC, TRNY, TRNS1) appear upregulated - this could be a technical artifact in some arrays (tRNA probes often pick up contaminating signal) or a real biological signal. I should note this as a potential artifact.

Also, many lncRNAs/MIRs (LOC105377700, CD81-AS1, LOC107984754, LOC107986183, MIR4647, MIR12136, MIR4426, MIR1244-1, MIR6717, MIR1825, MIR4721) - these are harder to interpret biologically.

Let me now write the response.

I should also note HSPA9-AS1 (down) and CNPY3-GNMT (down) - read-through lncRNAs.

OK let me write a comprehensive but focused response. I'll organize around:

1. Overall interpretation: MASH macrophage remodeling + inflammation + complement + sinusoidal + cell stress
2. Core programs (5 max):
   - Program 1: Macrophage remodeling (TREM2+ LAM expansion, Kupffer cell loss)
   - Program 2: Inflammatory/chemokine activation
   - Program 3: Complement suppression
   - Program 4: Sinusoidal endothelial and adhesion remodeling
   - Program 5: Hepatocyte stress response (proliferation, DNA damage, metabolic)
3. Key genes (10 max): TREM2, CXCL10, UBD, MARCO, CD163, MRC1, CR1, LYVE1, HS3ST2, FOXM1
4. Validation priorities (5 max)
5. Evidence grounding
6. Limitations

Let me write this now.</think>

# Multidimensional Interpretation of MASH vs. Healthy Liver Transcriptomic Signature

## 1. Overall Biological Interpretation

The supplied differential expression profile (100 selected genes, all FDR ≤ 1.8e-07, 51 upregulated / 49 downregulated, log2FC range −4.59 to +4.91) is dominated by a **coordinated macrophage/inflammatory/complement signature** rather than a hepatocyte-metabolic one. The single strongest individual change is **TREM2** (log2FC = +4.91, FDR = 3.9e-09), accompanied by a striking coincident downregulation of multiple canonical tissue-resident Kupffer cell markers (MARCO, CD163, MRC1, CD5L, TIMD4, SPIC, FOLR2, SIGLEC1, MPEG1, CSF1R). This opposing-direction pattern is the recognized transcriptional fingerprint of **TREM2⁺ monocyte-derived "lipid-associated macrophages" (LAMs) expanding while embryonically seeded Kupffer cells are lost** — a hallmark of human and murine MASH that has been reproduced across multiple scRNA-seq studies and is enriched in disease-activity rather than simple steatosis.

Layered on this macrophage program are: (i) **inflammatory chemokine/interferon signaling** (CXCL10↑, UBD↑, TNFRSF12A↑, DUSP8↑), (ii) **suppression of classical complement components** (CR1↓, CFP↓, CD5L↓) — consistent with the recurrent GO term "Regulation Of Complement Activation, Classical Pathway" surfaced by the pathway batch — and (iii) **loss of sinusoidal endothelial identity and cell-cell adhesion** (LYVE1↓, CDH5↓, VCAM1↓, PCDH20↓, CDH23↓, LDB2↓), linked to the GO term "Cell-Cell Adhesion Via Plasma-Membrane Adhesion Molecules". Smaller but coherent signals point to **heparan-sulfate remodeling** (HS3ST2↑, NDST3↓), **hepatocyte proliferation/DNA-damage stress** (FOXM1↑, TP53I3↑, EME1↑), and a **one-carbon/folate shift** (MTHFD1L↑, CBS↓). The recurrent literature match (PMID 39497821; "efferocytosis-related biomarkers… for MASH") and a metabolic-liver-disease progression signature (PMID 42089112) are externally concordant with the dominant macrophage/efferocytosis interpretation.

---

## 2. Core Biological Programs (≤5)

### Program 1 — TREM2⁺ Lipid-Associated Macrophage (LAM) Expansion with Loss of Tissue-Resident Kupffer Cells

- **Direction:** Up (TREM2 / CXCL10 / UBD / FABP5 / CAPG / MANF / TNFRSF12A) and Down (MARCO / CD163 / MRC1 / CD5L / TIMD4 / SPIC / FOLR2 / SIGLEC1 / SIGLEC11 / CSF1R / MPEG1 / LYVE1<sup>endo</sup>).
- **Representative GO / Reactome / Hallmark:** GO:0050776 "regulation of immune response"; KEGG hsa04145 "Phagosome"; Reactome "Innate Immune System"; closest Hallmark = "Inflammatory Response" + "Coagulation" (the latter because of VCAM1/CSF1R/TIMD4).
- **Why this is a coherent program:** The strongest positive effect in the entire table (TREM2↑) is anchored by a parallel coordinated *downregulation* of ≥10 known Kupffer cell identity genes. This bidirectional coupling is not expected from generic inflammation and is the molecular signature of macrophage pool repopulation. The STRING cluster (CD163-MRC1-SIGLEC1) and the OmniPath CSF1R–TREM2 signaling pair (ConnectomeDB2025) provide network-level support. STRING additionally links CD163 to MARCO via CD36, consistent with a shared macrophage/scramblase module.
- **Strength of evidence:** **Direct statistical evidence is strong** (multiple genes FDR < 1e-07, log2FC > 2). Network/ontology evidence is supportive but not independent of the same curated macrophage lists. No independent cohort statistic is supplied — direction in MASH is concordant with published scRNA-seq, but the user's literal statistic is the only direct evidence here.
- **Limitations:** Several macrophage markers (e.g., MARCO, CSF1R) also label sinusoidal endothelial or monocyte subpopulations, so single-gene attribution should be cautious; this is a compositional shift (Kupffer → monocyte-derived) and not a pure transcriptional program.

### Program 2 — Inflammatory Chemokine / Interferon-Stimulated Activation

- **Direction:** Up. CXCL10 (+3.46), UBD (+4.15), TNFRSF12A (+3.27), DUSP8 (+3.49), TSC22D1 (+1.45), MIR12136 (+3.18, though biologically a miRNA host).
- **Candidate pathway:** Reactome "Interferon Signaling" / "Cytokine Signaling in Immune system"; MSigDB Hallmark "Interferon Gamma Response" + "TNFA Signaling Via NFKB".
- **Why this is a coherent program:** CXCL10 is a canonical IFN-γ-induced chemokine driving recruitment of CXCR3⁺ T/NK cells; UBD (ubiquitin D / FAT10) is an IFN/lipopolysaccharide-inducible immunomodulator; TNFRSF12A (Fn14 / TWEAKR) is a stress-induced receptor up-regulated in injured hepatocytes and a known driver of NASH fibrosis. Together they indicate that the macrophage shift is **coupled** to a T-cell-recruiting and hepatocyte-stress chemokine program rather than a sterile M2 polarization.
- **Strength of evidence:** Multiple genes, strong effect sizes. External literature status (PMID 29503738 for CX3CR1-expressing immune cells; PMID 39497821 MASH biomarker paper) provides plausibility. **No independent cohort statistic is supplied.**
- **Limitations:** Some of these genes (e.g., TSC22D1, DUSP8) are also induced by stress hormones / glucocorticoids, so plate-level confounding is plausible.

### Program 3 — Classical Complement Suppression

- **Direction:** Down. CR1 (−3.61), CFP (−1.86), CD5L (−2.90), plus CR1↔C3 and CR1↔CFP STRING pairing.
- **Candidate pathway:** GO:0030450 "Regulation Of Complement Activation, Classical Pathway" (already highlighted by the RAG batch).
- **Why this is a coherent program:** Three independent components of the classical-pathway C3 convertase / regulatory axis (CR1 = receptor/regulator, CFP = properdin cofactor alternative, CD5L = soluble inhibitor of C5–C9 and efferocytosis facilitator) are jointly downregulated with FDR < 1e-07. Reduced CD5L is biologically consistent with impaired macrophage efferocytosis — a recognized MASH driver — and the RAG batch retrieved a MASH-specific machine-learning paper (PMID 39497821) that also classifies efferocytosis-related genes as MASH biomarkers.
- **Strength of evidence:** Direction is consistent across the three genes; STRING evidence supports a real C3-CR1-CFP neighborhood. The biology of *reduced* classical-pathway regulators in MASH is plausible if one accounts for macrophage subtype composition, but the alternative reading (loss of complement-replete Kupffer cells) cannot be separated from the Program 1 compositional shift with the uploaded data alone.
- **Limitations:** Strongly **confounded with cell composition**; cannot be interpreted as a hepatocyte-autonomous complement program without deconvolution.

### Program 4 — Sinusoidal Endothelial and Adhesion Remodeling

- **Direction:** Down. LYVE1 (−2.73), CDH5 (−1.38), VCAM1 (−2.38), PCDH20 (−4.59), CDH23 (−1.90), LDB2 (−1.53), PLXNB2 (−1.18); up: HS3ST2 (+3.72), TINAGL1 (−1.78, but ECM/laminin-binding).
- **Candidate pathway:** GO:0098742 "Cell-Cell Adhesion Via Plasma-Membrane Adhesion Molecules" (RAG batch); GO:0001525 "angiogenesis".
- **Why this is a coherent program:** LYVE1 is the defining marker of liver sinusoidal endothelial cells (LSECs); CDH5 (VE-cadherin), VCAM1, PLXNB2, and LDB2 are sinusoidal/junctional-identity genes. Their coordinated loss is the recognized LSEC "capillarization" signature of progressive MASH. The opposing-direction HS3ST2 / NDST3 pair suggests **heparan-sulfate remodeling** of the endothelial glycocalyx (STRING HS2ST1 hub connects both).
- **Strength of evidence:** Six-plus genes with FDR < 1e-06 representing a single cellular compartment; consistent with the literature on MASH capillarization. STRING pairs (CDH5-CTNNB1; HS3ST2-HS2ST1-NDST3) are network-correlated but not independent of the same compartment.
- **Limitations:** LSEC markers are notoriously sensitive to isolation/perfusion artifacts; the input should be interpreted as a **tissue-composite** signature, not a primary endothelial mechanism, without single-cell or histology confirmation.

### Program 5 — Hepatocyte Stress, DNA-Damage / Proliferation, and One-Carbon Shift

- **Direction:** Up for proliferation/DNA-damage genes (FOXM1 +2.14, TP53I3 +3.26, EME1 +1.88, MTHFD1L +1.72, CAST +4.02, CAPG +2.57, AJUBA +1.92); down for selected metabolic (CBS −1.25, SCLY −1.28, CNPY3-GNMT read-through −1.76).
- **Candidate pathway:** Hallmark "E2F Targets" / "G2M Checkpoint"; Reactome "DNA Repair"; KEGG hsa00670 "One carbon pool by folate" (MTHFD1L).
- **Why this is a coherent program:** A coordinated rise of FOXM1 (G2/M transcription factor), TP53I3 (p53-inducible oxidoreductase), and EME1 (DNA crosslink repair endonuclease) is the proliferation / DNA-damage response observed in MASH hepatocytes under lipotoxic and oxidative stress. MTHFD1L is the mitochondrial 10-formyl-THF synthetase frequently induced under oxidative stress; CBS / SCLY downregulation perturbs transsulfuration / selenocysteine metabolism, plausibly compounding oxidative stress.
- **Strength of evidence:** Effect sizes moderate; no enrichment P-value supplied; STRING FOXM1–CTNNB1–TCF7L1 cluster provides a mitotic / Wnt-handling network. The **proliferation vs. injury** interpretation is ambiguous without Ki-67/HIST1H staining.
- **Limitations:** CAST, CAPG, AJUBA are not exclusively hepatocyte; ribosomal / tRNA-derived reads (TRNK, TRNL2, TRNC, TRNY, TRNS1) are all upregulated and may indicate **either a genuine mitochondrial translational response or a probe/annotation artifact** — the latter should be excluded before any mechanistic claim.

---

## 3. Key Genes and Interaction Modules (≤10)

| # | Gene (direction, log2FC) | Role in programs | Gene-gene relationship category |
|---|--------------------------|------------------|--------------------------------|
| 1 | **TREM2** (↑, +4.91) | Defining LAM marker; Program 1 hub. | Direct physical interaction partner of CSF1R via OmniPath ConnectomeDB2025 (receptor complex); co-expressed with macrophage shift genes; gene-gene relationship category = **direct receptor signaling + co-expression**. |
| 2 | **CXCL10** (↑, +3.46) | Interferon-induced chemokine; Program 2. | Pathway co-membership with TREM2⁺ macrophages (cytokine-cytokine receptor interaction); co-expressed in MASH liver; not a direct physical interaction. |
| 3 | **UBD / FAT10** (↑, +4.15) | IFN/LPS-induced ubiquitin modifier; Programs 1 & 2. | Pathway co-membership and co-expression; direct interactome sparse. |
| 4 | **MARCO** (↓, −2.84) | Kupffer cell-residency marker; Program 1. | STRING-connected to CD163 via CD36 (co-expression/pathway co-membership; not a direct MARCO-CD163 binding). |
| 5 | **CD163** (↓, −2.52) | Resident macrophage scavenger receptor; Program 1. | STRING cluster with MRC1 and SIGLEC1 (pathway co-membership and co-expression). |
| 6 | **MRC1** (↓, −2.10) | M2-type mannose receptor; Program 1. | STRING pair with CD163 / SIGLEC1 (co-expression, not direct binding). |
| 7 | **CR1** (↓, −3.61) | Complement receptor; Program 3. | STRING-connected to C3 (selective biochemical interaction: CR1 binds C3b) and to CFP (classical-pathway co-membership). |
| 8 | **LYVE1** (↓, −2.73) | LSEC hyaluronic acid receptor; Program 4. | Pathway co-membership with CDH5 in LSEC identity; no direct physical interaction implied. |
| 9 | **HS3ST2** (↑, +3.72) | Heparan-sulfate 3-O-sulfotransferase; Program 4. | STRING-connected to NDST3 via HS2ST1 hub (pathway co-membership / same biosynthetic pathway, not direct binding). |
| 10 | **FOXM1** (↑, +2.14) | G2/M transcription factor; Program 5. | STRING-connected to CTNNB1 and TCF7L1 (Wnt / β-catenin network; this is pathway co-membership and literature co-occurrence, **not** a direct physical interaction). |

Note: **CD81-AS1** down (−2.96) is also notable as a long non-coding RNA; STRING/OmniPath give no direct physical interactions, so any claim is pathway co-membership / literature co-occurrence only.

---

## 4. Validation Priorities (≤5)

### Priority 1 — TREM2⁺ monocyte-derived macrophages as the cellular substrate of the macrophage shift
- **Category:** Biomarker / Interaction-network hypothesis.
- **Why prioritized:** TREM2 is the single biggest effect in the dataset and the macrophage shift is the most parsimonious explanation. Without single-cell / spatial confirmation, this is a strong *supported hypothesis* that could be a Kunze-arithmetic artifact (cell-composition change).
- **Current evidence:** TREM2↑ + coordinate downregulation of ≥10 Kupffer markers with FDR < 1e-07; STRING and OmniPath supporting interactions.
- **External evidence:** Concordant with published MASH scRNA-seq literature; PMID 39497821 validates efferocytosis-related genes as MASH biomarkers.
- **Next step:** **Multiplex immunofluorescence** (TREM2 + CD68 + MARCO + CD163) on the same FFPE cohort, and flow cytometry on fresh liver digest for TREM2⁺ CD163⁻ monocyte-derived macrophages. Cell-type **deconvolution** of the bulk RNA-seq matrix (CIBERSORTx or MuSiC) with a MASH-specific signature matrix.
- **Evidence label:** **Supported hypothesis** for the macrophage shift; **exploratory hypothesis** for LAM = causal driver.

### Priority 2 — Classical-complement suppression as MASH-relevant or a Kupffer-cell proxy
- **Category:** Confounding / composition check.
- **Why prioritized:** CR1 / CFP / CD5L are all substantially enriched in resident Kupffer cells; their downregulation may simply reflect the loss of this compartment. Mis-attribution could lead to misguided complement-inhibitor therapy.
- **Current evidence:** Three complement genes down, FDR < 1e-07; STRING C3-CR1-CFP neighborhood.
- **External evidence:** Unknown for this specific cohort; mechanistic complement work in MASH is mixed.
- **Next step:** Measure plasma C3, C4, and C3a desArg and liver C3 deposition in MASH vs. control in an independent cohort; specifically correlate protein levels with hepatic macrophage (TREM2 / MARCO) abundance.
- **Evidence label:** **Exploratory hypothesis**; could be **insufficient evidence** without deconvolution.

### Priority 3 — CXCL10 / UBD inflammatory program as a biomarker of MASH activity
- **Category:** Biomarker / mechanistic hypothesis.
- **Why prioritized:** CXCL10 is a clinically measurable serum chemokine; UBD is a candidate plasma biomarker. Both are large-effect, statistically robust, and orthogonal to the macrophage composition question.
- **Current evidence:** CXCL10 (+3.46, FDR 1.2e-07), UBD (+4.15, FDR 1.3e-10).
- **External evidence:** CXCL10 is a known IFN-γ/NASH readout; PMID 29503738 supports CX3CR1-axis roles.
- **Next step:** Quantitative ELISA of CXCL10 and UBD in paired serum samples from MASH vs. controls and correlation with NAS / fibrosis stage; replicate in a published external dataset (e.g., GSE130970).
- **Evidence label:** **Supported hypothesis** for association; **exploratory hypothesis** for causal role.

### Priority 4 — HS3ST2 / NDST3 heparan-sulfate remodeling as a sinusoidal injury readout
- **Category:** Mechanistic hypothesis / biomarker.
- **Why prioritized:** This is a clean opposing-direction pair (HS3ST2↑ +3.72, NDST3↓ −2.67) within a single biosynthetic pathway (HS2ST1 hub in STRING), with no known precedent in MASH literature — making it a high-novelty target.
- **Current evidence:** Two genes, FDR < 1e-07, opposing directions, shared pathway.
- **External evidence:** No independent cohort statistic supplied; pathway/ontology evidence is contextual.
- **Next step:** Validate HS3ST2 and NDST3 transcript / protein in an independent MASH cohort; use cultured primary LSECs ± fatty-acid stress to test whether the HS3ST2:NDST3 ratio is a primary response or a secondary capillarization marker.
- **Evidence label:** **Exploratory hypothesis**; novelty is high, evidence depth is shallow.

### Priority 5 — FOXM1 / TP53I3 / EME1 hepatocyte proliferation-DDR axis as a driver of MASH-associated HCC risk
- **Category:** Mechanistic hypothesis / therapeutic target.
- **Why prioritized:** NASH is the fastest-growing indication for HCC; the proliferation/DNA-damage triplet is a rational early lesion.
- **Current evidence:** FOXM1 (+2.14), TP53I3 (+3.26), EME1 (+1.88) all upregulated with FDR < 1e-07, network-linked via CTNNB1.
- **External evidence:** FOXM1 is a recognized MASH-HCC driver in rodent models; no independent human cohort statistic supplied in this dataset.
- **Next step:** Western blot for FOXM1 and γH2AX in MASH vs. control liver; cross-reference with TCGA-LIHC for tumor-adjacent expression.
- **Evidence label:** **Supported hypothesis** for the program being present; **exploratory hypothesis** for the NASH→HCC causal model.

---

## 5. Evidence Grounding

- **Direct evidence from the uploaded dataset:** log2FC, P, and FDR are the *only* sources for the claim "this gene is differentially expressed in MASH liver vs. healthy control." They are the sole quantitative basis for every program above.
- **Pathway / ontology evidence:** Recurrence of "Cell-Cell Adhesion Via Plasma-Membrane Adhesion Molecules" (GO:0098742), "Regulation Of Complement Activation, Classical Pathway" (GO:0030450), and "Negative Regulation Of Amyloid Fibril Formation" (GO:1905907) was supplied by the RAG batch. These are *contextual* — they label the cohort but are not independent replication.
- **Protein interaction / regulatory evidence:** STRING (C3-CR1, CD163-MRC1-SIGLEC1, CD36 cluster, HS2ST1 hub, CTNNB1-FOXM1-TCF7L1) and OmniPath (CSF1R-TREM2; FGFR1-FGFRL1 / TNFRSF12A) provide network-level support. **None of these is independently gathered wet-lab interaction evidence in this cohort.**
- **Disease-association evidence:** OpenTargets, GWAS, ClinVar records exist for 89 / 100 / 82 genes respectively, but no individual gene is established by *this* dataset as causal.
- **Tissue / expression evidence:** GTEx (75/100) and HPA (66/100) confirm that the implicated genes are expressed in liver and in macrophages / endothelial cells respectively, supporting compartment plausibility.
- **Therapeutic evidence:** ClinicalTrials.gov (40/100) and ChEMBL (33/100) and CIViC (4/100) records exist, but **the existence of any drug targeting a gene/pathway is not, by itself, evidence that the gene is an effective MASH therapeutic target** (explicit policy).
- **Published literature evidence:** PMID 39497821 (MASH efferocytosis biomarkers) and PMID 42089112 (MASH progression signature) are concordant with Programs 1 and 2; PMID 29503738 supports the macrophage/CX3CR1 axis; Europe PMC 42074521 (S100A14 lactylation biomarkers) and 42089112 (miR-26a-5p in MASH) are plausibility checks, not replication.
- **Independent cohort validation:** **None performed or supplied.** The uploaded table is the only direct statistical evidence.

**Potential conflicts:** TREM2 is canonically an *M2-like* gene, yet CXCL10 and UBD are *M1/IFN-induced* — the program is therefore not a clean M2 shift; this is internally consistent with the published MASH-LAM literature but should be flagged as a mixed-polarity signature, not a uniform one.

---

## 6. Limitations and Alternative Explanations

1. **Cell-composition confounding (largest risk).** The dominant signature is a macrophage-compartment shift (TREM2⁺ LAMs in vs. Kupffer cells out) and an LSEC remodeling signature. Without single-cell / spatial validation, the data cannot distinguish a **transcriptional program** from a **cellular-composition change**. Deconvolution against a MASH-specific reference (e.g., Ramachandran et al. *Nature* 2019) is the minimal next step.
2. **Disease severity and stage heterogeneity.** No clinical metadata (NAS, fibrosis stage, BMI, diabetes status) is supplied. The interpretation assumes a uniform "MASH" population; in reality, the macrophage/vascular programs can move in opposite directions across F0-F4.
3. **Probe / annotation artifacts.** Multiple **mitochondrial tRNA** transcripts (TRNK, TRNL2, TRNC, TRNY, TRNS1) are upregulated with very large log2FC. These may be a biological mitochondrial-translation response (consistent with UQCRBP1↑ and CYCS↑) or a cross-hybridization artifact on the array. They should be **excluded from any mechanistic claim** until validated by an orthogonal assay.
4. **Long non-coding and miRNA host genes (LOC105377700, CD81-AS1, LOC107984754, MIR12136, MIR4647, MIR4426, MIR1244-1, MIR4721, DIO3OS, NUCB1-AS1, MROH2B-DT, MRPL1-AS1, HSPA9-AS1, CNPY3-GNMT, LINC01485, LOC107986183, LOC107986158, LOC102724560, LOC105371873).** These comprise roughly a quarter of the list; their magnitude ranking should not be interpreted as biological importance because of inconsistent annotation and isoform collapse.
5. **Association vs. causation.** None of the uploaded values can establish causality. The macrophage shift, complement suppression, and HS3ST2:NDST3 imbalance are *correlated* with MASH; experimental perturbation (conditional knockouts, antibody-mediated depletion) is required before any is treated as a **driver**.

---

### Bottom line
The dataset is a textbook MASH-vs-control transcriptomic signature whose organizing principle is **monocyte-derived TREM2⁺ macrophage expansion alongside resident Kupffer cell and sinusoidal endothelial loss**, coupled to an **inflammatory chemokine (CXCL10/UBD) module**, a **classical-complement suppression pattern** that is also a cell-composition proxy, an **HS3ST2:NDST3 heparan-sulfate remodeling signal**, and a **hepatocyte proliferation/DNA-damage readout (FOXM1/TP53I3/EME1)**. All major claims are anchored in the uploaded statistics; **external cohort replication was not performed**, so the conclusion that these programs are causal drivers of MASH — rather than consequences of inflammation, cellular composition, or disease stage — remains an exploratory hypothesis requiring single-cell confirmation, deconvolution, and perturbation studies.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=3, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 93/100 selected items (records returned); cbioportal 85/100 selected items (records returned); chembl 33/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 82/100 selected items (records returned); ensembl 42/100 selected items (partially returned; some queries failed); europepmc 897 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 75/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 66/100 selected items (records returned); humanbase 91/100 selected items (records returned); intact 69/100 selected items (records returned); mygene 96/100 selected items (records returned); omnipath 40/100 selected items (records returned); opentargets 89/100 selected items (records returned); pubmed 612 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 69/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 69/100 selected items (records returned)
Local databases: gutmgene 1/100 selected items (records returned); hmdb 28/100 selected items (records returned); string 67/100 selected items (records returned); trrust 17/100 selected items (records returned)
